[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
9-Dec-2013

[ | E-mail ] Share Share

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center

Penicillin equally effective as 'big gun' antibiotics for treating less severe childhood pneumonia

Children hospitalized for pneumonia have similar outcomes, including length of stay and costs, regardless of whether they are treated with "big gun" antibiotics such as ceftriaxone or cefotaxime or more narrowly focused antibiotics such as ampicillin or penicillin, according to a Vanderbilt study published in Pediatrics.

Study authors said the findings are important because pneumonia is one of the most common reasons for hospitalization among U.S. children and because broad-spectrum antibiotics are frequently overprescribed, leading to antibiotic resistance.

"Sometimes there is a perception, not restricted to pneumonia, that the use of a broad spectrum antibiotic, a big gun, is going to be the best treatment for all patients. This perception can complicate the selection of antibiotics especially when there is limited information to support the decision," said senior author Carlos G. Grijalva, M.D., MPH, assistant professor of Health Policy. "To help inform those decisions, this study compared two pneumonia treatment regimens, a big gun (broad spectrum antibiotics) vs. a small gun (narrow spectrum antibiotics), and found there were no significant differences in clinical outcomes or associated costs."

In Summer 2011, the Pediatric Infectious Diseases Society and Infectious Diseases Society of America (PIDS/IDSA) released joint community-acquired pneumonia guidelines that recommend narrow-spectrum antibiotic therapy for most children hospitalized with pneumonia but, until now, few studies had compared the effectiveness of this strategy relative to use of broad spectrum antibiotics.

Using data from 43 children's hospitals in the U.S., the authors compared outcomes among children 6 months to 18 years of age hospitalized for pneumonia between 2005 and 2011, receiving either ampicillin or penicillin (narrow spectrum) or a third generation cephalosporin (ceftriaxone or cefotaxime,[broad spectrum]). According to the PIDS/IDSA guidelines, both treatment strategies are effective for disease caused by Streptococcus pneumoniae, the most common bacterial cause of pneumonia.

Lead author Derek J. Williams, M.D. MPH, assistant professor of Pediatrics, said doctors worry about increases in unnecessary use of broad spectrum antibiotics because they drive increases in disease caused by antibiotic-resistant bacteria.

"We have seen increases in use of broad spectrum antibiotics and concurrent increases in disease caused by resistant bacteria. For this study, we hypothesized that narrow and broad-spectrum antibiotics would have similar effectiveness in the treatment of childhood pneumonia. Our findings support the preferential use of narrow spectrum antibiotics as first-line therapies for most children hospitalized with pneumonia," Williams said.

"Although interventions such as the introduction of the pneumococcal conjugate vaccines into the U.S. childhood vaccination schedule in 2000 have led to reductions in pneumococcal disease in general and reductions in disease caused by vaccine strains resistant to antibiotics, additional actions are necessary to inform antibiotic selection and to continue reducing antibiotic resistance."

In the study, nearly 90 percent of children received broad-spectrum therapy, compared with only 10 percent receiving narrow-spectrum therapy.

"The 2011 PIDS/IDSA guidelines recommending ampicillin or penicillin represents a major shift toward more narrowly focused treatment, and this is one of the first studies that directly compared these agents against the more commonly used broader spectrum therapies," Williams said. "Although ampicillin or penicillin therapy was as effective as the third generation cephalosporins, use of the narrower spectrum drugs was very uncommon prior to release of the guidelines. In the near future, it would be interesting to evaluate whether the release of the consensus guidelines and related efforts facilitate widespread adoption of the new treatment recommendations."

###



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.